Perrigo's 25% Post-Earnings Jump: Real Turnaround or Just Cheap EPS?

The market rewarded cost control more than a clean sales recovery

Perrigo shares jumped 25.14% in pre-market trading after a quarter in which core net sales declined 3.1% and core adjusted gross margin fell 150 basis points. The market's reaction says investors were more encouraged by a cleaner bottom line than by a full demand recovery.

That tension is the story. The stock got happier, but the core business still shrank.

The quarter was marked by softer sales and narrower gross margin, even as the company pressed ahead with its Three-S plan. In that setup, better cost control mattered more than proof that end demand had fully turned.

Adjusted EPS also got some help from temporary items. Management said it benefited from one-time benefits tied to a CEO transition and tariff reversal. That does not make the quarter bad; it just means not all of the earnings support was recurring.

The leadership change adds context, not operating proof. Perrigo announced the leadership transition in June 2026, so it is still early to read the quarter as the start of a clean new phase.

U.S. service levels and infant formula are the clearest positives

The strongest operating improvement was in execution, not earnings presentation. Perrigo said U.S. service levels were U.S. service levels up 1,600 basis points to 91%. For a business built partly on store-brand and contract supply, better fill rates matter because they support retailer relationships and future order stability.

That is a more durable signal than a one-quarter accounting improvement. If products are on the shelf when retailers want them, Perrigo is better positioned to keep and grow that business over time.

Infant formula was the clearest growth driver in the quarter. Infant formula net sales grew 23%, and infant formula operating income improved by about $16 million. That helped offset weakness elsewhere.

The broader portfolio was not weak across the board. Perrigo said it 50 basis points of market share growth in both U.S. store-brand OTC and key European brands. That suggests the products still have traction even in a soft category backdrop.

Still, the quarter was uneven. Self-care operating income fell 16.2%, specialty care operating income declined about 28%, and the sales mix was still soft, with pricing decreased 0.7%. The business looks healthier in places, but not fully restored.

The bull case depends on the second half, not just a one-quarter earnings beat

Bulls are not focused on this quarter alone. They are focused on what management thinks can happen next. Perrigo reaffirmed a sequentially stronger second half, and management said the year still has a heavy weighting toward the second half. If sales improve as expected, fixed-cost leverage could help margins.

There are a few reasons for that view: - Europe was hurt by retailer destocking, and management pointed to easing year-over-year comparisons later in the year. - The company still has $80 million to $100 million in savings targeted by 2027. - Better service levels could help preserve retailer business and support more stable volumes.

That is the core bull argument: the next leg of the story does not have to come from a dramatic sales rebound if operations, comparisons, and savings can improve together.

Bears have a simpler objection: the quarter still looked too much like temporary support masking a soft business. The same earnings line that helped the rally also included one-time benefits tied to a CEO transition and tariff reversal. If those boosts fade, operations need to do more of the work.

The balance sheet also leaves less room for error. Perrigo reported $83 million in cash from operating activities and $400 million of cash and cash equivalents, against $3.3 billion of total debt. That is not a crisis, but it is not much cushion either.

What would confirm a real recovery in the next quarter

The next few quarters should show whether this was the start of a turnaround or just a relief move.

Signals that would strengthen the case

• Pricing stabilizes. Last quarter, pricing decreased 0.7%. A neutral or better reading would suggest demand is less pressured.
• Sales stop falling. Sales were down 3.2% year over year. Flat or positive growth would be the simplest sign of recovery.
• Service levels hold. If Perrigo can keep near that 91% range, it would support the view that retailer partnerships are improving.
• Share gains continue. Perrigo already showed 50 basis points of market share growth in key channels. Another round would reinforce product traction.

Signals that would weaken the rally

• Margins get squeezed again. Core adjusted gross margin declined 150 basis points to 37%. If that pressure returns, cost control alone is not enough.
• Weak segments slip again. Self-care and specialty care were both down meaningfully. Another soft showing would say the problem is still operational, not cosmetic.
• The second-half lift does not arrive. If the later part of the year fails to prove sequentially stronger, the leverage case gets much harder to defend.

The Dermacosmetics divestiture is complete, and Perrigo is still reviewing other parts of the portfolio. That can help focus the business, but it can also keep management's attention spread across strategic options. For now, the cleanest test is simple: do sales, pricing, and segment profits improve together?